Essex pharmaceuticals inc telefoonnummer
CYC065, a cyclin dependent kinase (CDK) inhibitor, in patients with advanced cancers.
Sapacitabine (CYC682 an oral nucleoside analogue prodrug that acts through a novel mechanism.
Career opportunities at GSK, discover the work we do and the opportunities that exist, from research and development through to making our products available to those who need them.
By continuing to browse the site you are droom vrouw wilde 2016 facebook consenting to their use.
Seliciclib (CYC202 a novel, first-in-class, orally available, cyclin dependent kinase (CDK) inhibitor.Unable to find any suggestions for your query.Health for all, our medicines, vaccines and consumer healthcare products are improving quality of life for patients and consumers around the world.We are different and we are the same.(nasdaq: cycc, nasdaq: cyccp) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates.
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare.
Our Pipeline, cyclacel is a pioneer company in the field of cell cycle biology with a vision to improve patient healthcare by translating cancer biology into medicines.
The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with brca positive, advanced solid cancers.
GSK, about us, we are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.Read our stories 22nd in The Times and The Sunday Times Good University Guide 2018.Gold for teaching excellence (TEF 2017).News Essex Blades bounce back, our Essex Blades womens basketball team are celebrating after securing a historic league title.Cyclacel's transcriptional regulation program is evaluating.